The 2020 Encephalitis pipeline report presents a comprehensive overview of the research and development of Encephalitis drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Seven drugs in Pre-clinical phase, one drug in Phase 1 and one drug in Phase 2
As of February 2020, the Encephalitis pipeline remains robust with 9 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Encephalitis treatment. Diverse types of targeted therapies are being explored through clinical trials including CD20 antigen inhibitor; NMDA receptor agonist; Immunostimulants.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Encephalitis drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
Our online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
• The report scope comprises of both pre-clinical phase and clinical phase development drugs for Encephalitis development
• Encephalitis pipeline compounds and molecules under study by both large scale and small companies are included in the report
• Encephalitis pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
• Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
• Further, orphan drug status, fast track designation, different grants awarded and special status for Encephalitis pipeline candidates included
• Business overview and snapshot of all companies involved in Encephalitis pipeline are included
• Latest market and pipeline developments are provided in the report
Encephalitis pipeline companies included in the report are- CEL-SCI Corp, Cerion LLC, Cour Pharmaceutical Development Company Inc, F. Hoffmann-La Roche Ltd, Knight Therapeutics Inc, NeurMedix Inc, Olymvax Biopharmaceuticals Inc, Sage Therapeutics Inc
Encephalitis pipeline drugs profiled in the report include- CEL-1000, Cerium dioxide, Immune modifying particle (IMP) technology for Encephalitis, ocrelizumab, miltefosine, NE3413, 13-valent pneumococcal vaccine, 23-valent pneumococcal vaccine, SAGE-718